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Increasing evidence suggests that human cytomegalovirus (HCMV), a beta-herpes virus
that chronically infects human beings, is associated with colorectal cancer (CRC). The viral
nucleic acids specifically localized to the neoplastic mucosal epithelium of CRC, while
tumoral presence of HCMV independently predicted a poor outcome in elderly patients. In
the past decade, the concept of “oncomodulation” of HCMV in human cancers has been
formulated. In CRC, changes in the tumor microenvironment are closely related to cancer
behavior and prognosis, while the underlying mechanism driving these changes remains
unclear. As HCMV affects multiple cellular functions, including signal pathways that regulate
angiogenesis, apoptosis, cell invasiveness, and anti-cancer immunity, the virus potentially
exerts oncomodulatory effects in the tumor microenvironment of CRC. Here, we summa-
rize the current knowledge about the association between HCMV and CRC and suggest
future perspectives on both research and anti-cancer therapy of CRC.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most commonly found
cancers leading to significant mortality and morbidity. Despite
efforts and progress made in the treatment, the survival rate is
still low unless found and treated early (1). Multiple factors con-
tribute to the outcome of CRC. The gold standard for outcome
prediction is based on the tumor–node–metastasis classification
of the Union for International Cancer Control (TNM-UICC).
However, since the pathogenesis of CRC involves multiple and het-
erogeneous pathways, an observation based merely on anatomy
and histology may sometimes be misleading. Patients of the
same stage frequently have dramatically different outcomes. Such
dis-concordance may result from changes in tumor microenvi-
ronments that have been shown to be closely associated with
prognosis (2). Nevertheless, the underlying mechanisms driving
these microenvironmental changes in cancer behavior and subse-
quent local anti-cancer immunity in the tumor microenvironment
remain obscure.
Virus as an oncogenic agent has long been recognized, for exam-
ple, human hepatitis B and C viruses to hepatoma and human
papilloma virus to cervical cancer. A certain herpes group virus,
such as Epstein-Barr (EB) virus, has been shown to relate to
nasopharyngeal carcinoma and Burkitt’s lymphoma. However,
human cytomegalovirus (HCMV), a beta-herpesvirus that con-
tains many potential viral onco-proteins, has not been categorized
as an oncogenic virus till now. This virus infects 60–90% of
the general population and is regarded as an oncomodulatory
virus because of its effects on cell-cycle progression, mutage-
nesis, angiogenesis, and immune evasion (3–5). It was a long
debate whether HCMV may act as an oncomodulatory virus.
First, whether HCMV can be found in various tumorous tissues
is skeptical, although its gene components and gene products had
been detected in a number of human cancers (6–10). It is much
clearer now HCMV can be detected in a certain tumors, includ-
ing CRC. In CRC, several studies have identified HCMV in the
tumor tissues (11–13). We previously reported that ∼40% of the
CRC specimens were positive for HCMV (13). Later, we found
tumoral presence of HCMV is associated with an unfavorable out-
come in elderly CRC patients and predicts a shorter disease-free
survival, independent of that expected by the TNM stage (14).
Such findings imply that HCMV may affect the tumor microen-
vironment of CRC via a certain immune pathway. Theoretically,
upon infection, HCMV is able to up-regulate different host cel-
lular signal pathways, growth factors, and cytokines, resulting in
enhanced cell survival, proliferation, and angiogenesis (15). As
such, HCMV appears to regulate the malignant behavior of tumor
cells, implying an oncomodulatory role for the virus.
THE ASSOCIATION BETWEEN HCMV AND OUTCOME OF CRC:
INCREASING EVIDENCE
HCMV PREFERENTIALLY INFECTS THE TUMORAL EPITHELIUM OF
COLORECTAL CANCER
Using paired tumor and adjacent non-neoplastic CRC specimens,
we recently reported that HCMV preferentially infects the neo-
plastic epithelium of CRC. HCMV DNA was detected by PCR
in 42.3% (69/163) of the tumor specimens, while only 5.6%
(14/163) samples of adjacent non-neoplastic tissue were positive
for HCMV (p< 0.0001) (13). Significantly higher viral copies

























































Chen and Chan Human cytomegalovirus in colorectal cancer
were found in the tumor specimens than the adjacent non-
neoplastic tissue specimens. By in situ hybridization, the nucleic
acids of HCMV specifically localized to the cytoplasm of neo-
plastic epithelium, but not the submucosa, stroma, or inflamma-
tory infiltrations surrounding the tumor epithelium. These results
indicate that HCMV preferentially infects, or reactivates in, the
tumor epithelium of CRC, and is concordant with several pre-
vious studies that reported positive detection of HCMV in CRC
(11, 12).
However, detection of HCMV in CRC had been associated with
controversial results. (16–19). Negative detection of HCMV may
be attributed to several factors. Among the various techniques
used, a PCR-based detection of viral nucleic acids is both rapid
and sensitive, and is the most widely applied on detecting HCMV
in clinical samples. However, the selection of genes, the primer
design, and the quality and type of samples can all have substan-
tial influence on the result (20, 21). PCR detection of viral nucleic
acids may fail if the tissue has been processed extensively by forma-
lin, which causes fragmentation of DNA (22, 23). Frozen samples,
on the other hand, are more suitable for DNA preservation and
subsequent PCR detection (24, 25). Moreover, HCMV may only
infect malignant cells that are at specific stages of cell differentia-
tion and maintains a “low-grade infection” status in tumor (20, 26,
27). If the sample volume is too small, a false negative detection is
expected.
TUMORAL PRESENCE OF HUMAN CYTOMEGALOVIRUS IS ASSOCIATED
WITH SHORTER DISEASE-FREE SURVIVAL IN ELDERLY PATIENTS WITH
CRC
The relationship between HCMV and the outcome of CRC was
demonstrated in our recent study in which an association between
HCMV and a poor survival outcome in the elderly patients was
found. Significant interaction is seen between HCMV and the
elderly. In the elderly, HCMV tends to get reactivated more fre-
quently because of the age-related decline of cell-mediated immu-
nity (28, 29). On the other hand, chronic cytomegaloviral infection
is detrimental to the older population, associated with increased
mortality in elderly (30). The underlying mechanism may be that
chronic HCMV infection results in phenotypic and functional
alterations of adaptive immunity in the elderly, a status referred to
as “immunosenescence” (31–34).
We recently investigated the relationship between tumoral pres-
ence of HCMV and the outcome of elderly patients with CRC. In
the 81 patients who underwent curative surgery, the 39 patients
with HCMV-positive tumors had a lower disease-free survival
rate compared with those without HCMV in tumor (P= 0.024).
For patients with stage II or III diseases, tumoral HCMV status
correlated with disease-free survival more closely than the tumor-
node-metastasis (TNM) staging method. Using a multivariate Cox
proportional-hazards model, tumoral infection by HCMV inde-
pendently predicted disease recurrence in 5 years (hazard ratio,
4.42; 95% confidence interval, 1.54–12.69; P= 0.006). It is sur-
prising that within specific tumor stages, tumoral presence of
HCMV correlated with the outcome more closely than the tra-
ditional histopathological staging method. Such finding argues
for an important role that the virus may play in the tumor
microenvironment of CRC.
PERSPECTIVES OF THE ONCOMODULATORY ROLE OF HCMV
IN CRC
HCMV AND ANTI-CANCER IMMUNITY IN THE CANCER
MICROENVIRONMENT
HCMV and tumor-associated macrophages
Tumor-associated macrophages (TAMs) are derived from blood
monocytes that are recruited to the tumor. Macrophages can be
activated to either M1, the anti-tumor, or M2, the pro-tumor,
polarization states depending on the microenvironment stimuli.
The M1 macrophages are part of the T-helper (TH) 1 response
and are potent effectors against intracellular pathogens and tumor
cells. On the other hand, the M2 macrophages are involved in pro-
moting angiogenesis, tissue remodeling and repair, and are part of
the TH2 response. TAMs with M2 polarization are a major tumor-
infiltrating cell population (35). High TAM density in tumors is
now recognized as a poor prognostic sign in CRC (36).
When directly infecting the monocyte, HCMV renders mono-
cyte differentiation toward an M1 macrophage (37). However,
according to a recent study of human glioma, HCMV encodes
an interleukin (IL)-10 homolog, the cmvIL-10, which binds to
the human IL-10 receptor. Binding of cmvIL-10 renders the
monocytes in glioma to assume an M2 phenotype and turns
the anti-cancer immunity toward the immunosuppressive and
tumor-propagating phenotype (38). It would be valuable to study
whether the presence of HCMV in CRC was also associated with
a tumor-propagating phenotype of TAM.
HCMV and tumor-infiltrating T cells
Using immunohistochemical staining, quantitative PCR, and
large-scale flowcytometry, recent studies have demonstrated the
critical role of localized adaptive immune reaction in the progno-
sis of cancer behavior and prognosis (39, 40). The T cell-mediated
immunity within the tumor tissue predicts the outcome of CRC
independently to that of the traditional TNM-UICC stage of
the tumor (40). In CRC, a shift from TH1 to TH2 response in
CD4+ lymphocytes was noted (41). Such shift from TH1 to TH2
polarization of CD4+ lymphocytes renders the tumor-specific
cytotoxic CD8+ inactive. CRC also shows high levels of MHC
class-I alteration, with loss or downregulation of class-I MHC
molecules resulting from alteration in processing or presentation
(42, 43). The overall effect is immunosuppression and tolerance of
tumor growth. The underlying mechanism driving the alteration
in T cell-mediated immunity within the tumor microenvironment
remains obscure.
Interestingly, HCMV infection results in an immunosuppres-
sive status resembling to that found in CRC. To escape the surveil-
lance of cytotoxic T cells, HCMV encodes several viral genes (US2,
3, 6, 11) that downregulate the level of MHC class-I molecules on
the surface of infected cells (44). In organ transplant recipients,
who suffer from active HCMV diseases, the transcription of IL-10
and transforming growth factor (TGF)-β is significantly increased,
while the expression of interferon (IFN)-γ is reduced, suggesting a
shift from pro-inflammatory TH1 to the immune-tolerogenic TH2
response and resemble that found in CRC (45, 46).
In a small number of CRC samples, we analyzed the transcrip-
tion levels of signal pathways of the major TH subsets, includ-
ing TH1, TH2, regulatory T (Treg), and a newly defined subset,
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the TH17 that has recently been correlated to a poorer out-
come of CRC (47, 48). We found a higher transcription level
of IL 17 – the signature cytokine of TH17 cells – in HCMV-
positive tumors (14). Based on this finding, we speculate that
HCMV may be one of the underlying forces that drive the alter-
ation of anti-tumor immunity in the tumor microenvironment
of CRC.
HCMV INFECTION AND THE CELLULAR SIGNAL PATHWAYS THAT
CORRELATE WITH CANCER PROGRESSION
HCMV and cyclooxygenase-2 pathway
Cyclooxygenase (COX) is a key enzyme in the prostaglandin
biosynthetic pathway. COX-2, the inducible isoform of COX, has
received considerable attention due to its role in human cancers.
Activation of the COX-2 activity in tumor tissue leads to promo-
tion of angiogenesis, resistance to apoptosis, immune modulation,
and increase of cell invasiveness and metastasis (49–51). In CRC,
overexpression of COX-2 in CRC tissues correlates with poor prog-
nosis (52), while inhibition of the COX activity by non-steroidal
anti-inflammatory drugs (NSAIDs) results in protective effects for
CRC (53–55).
Human cytomegalovirus is also an inducer of COX-2, which
plays an important role in viral replication (56). In permis-
sive cells, inhibition of COX-2 results in marked reduction of
HCMV (57). It was previously reported that COX-2 expression
in CRC was concordant with areas of HCMV IE1-72 and pp65
immunoreactivity (12).
HCMV may promote angiogenesis in cancer
Induction of angiogenesis is one of the key factors that promote
tumor growth and cancer survival. The microvascular density of a
tumor has prognostic significance and predicts survival in patients
with CRC (58).
Mounting evidence suggests that HMCV may promote angio-
genesis. HCMV-infected cells directly induce angiogenesis by
secreting VEGF and other angiogenic factors (59), promoting vas-
cular tube formation (60). The HCMV gene US28 was shown to
be involved in the HCMV-induced angiogenic phenotype (61).
Analysis of clinical glioblastoma specimens revealed that US28
co-localized with several factors of angiogenesis (62).
HCMV promotes cell proliferation and inhibits apoptosis
Human cytomegalovirus is found to promote cell proliferation in
cancer. In a mouse model of glioblastoma, cytomegalovirus infec-
tion enabled the malignant cells to survive and multiply, leading to
shorter survival (63). HCMV also encodes multiple antiapoptotic
proteins, including the viral mitochondrion-localized inhibitor of
apoptosis (vMIA) or UL37 exon 1, UL36, and UL38 proteins, to
prevent host cells from programed death and to support viral
survival (64, 65).
HCMV infection alters the expression of matrix metalloproteinases
that are important in cancer metastasis
Matrix metalloproteinases (MMPs) are zinc-dependent endopep-
tidases. These enzymes are capable of degrading extracellular
matrix proteins and play a major role on cell behaviors such as cell
proliferation, migration, differentiation, angiogenesis, apoptosis,
and host defense (66). The expression levels of some MMPs are
correlated with stage of disease and/or prognosis (67).









Valganciclovir Oral Same as ganciclovir
Cidofovir Intravenous Nephrotoxicity
Foscarnet Intravenous Nephrotoxicity
Human cytomegalovirus infection is associated with a signifi-
cant alteration of MMPs in mRNA, protein, and functional levels
(68). Among them, MMP-9 negativity is associated with poor sur-
vival, while its positivity predicts a favorable outcome of CRC (69).
A reduction in MMP-9 mRNA, protein, and activity levels but
increased tissue inhibitor of matrix proteinases (TIMP)-1 mRNA
and protein levels was found after HCMV infection (68). MMP-9
mRNA expression was affected by an immediate-early or early viral
gene product, whereas TIMP-1 mRNA expression was affected by
late viral gene products. Furthermore, a higher mRNA level of
MMP-1, a marker for hematogenous metastasis of CRC (70), had
been demonstrated in HCMV-positive clinical specimens (71).
CAN ANTI-HCMV TREATMENT CHANGE THE OUTCOME OF CRC?
Traditional treatments for CRC include surgery, radiotherapy,
and chemotherapy. Introducing an anti-viral agent or anti-viral
immunotherapy for CRC has never been tested. Based on afore-
mentioned evidence for HCMV as an oncomodulatory agent, it
is justifiable to test the hypothesis that treating elderly patients
whose tumor is positive for HCMV may improve the outcome.
For HCMV infection, there are currently four anti-viral drugs
licensed for treatment: ganciclovir, valganciclovir, cidofovir, and
foscarnet (Table 1). Ganciclovir is a synthetic analog of deoxy-
guanosine. It is the first anti-viral agent approved for treatment
of cytomegaloviral disease and remains the first-line treatment
(72). Valganciclovir is the L-valyl ester prodrug of ganciclovir,
with excellent bioavailability equivalent to that of intravenous
ganciclovir. Both drugs have the major adverse effect of cytope-
nia. Cidofovir is a broad-spectrum anti-viral agent with potency
against many DNA viruses including smallpox virus (73). How-
ever, severe renal toxicity limits its use as an anti-viral agent.
Foscarnet is usually considered as second-line therapy for patients
who are failing ganciclovir therapy due to major side effects or
viral resistance (72).
Supportive data from glioblastoma trial may render this notion
promising. In a randomized double-blind trial, patients with
HCMV-positive glioblastoma were treated with valganciclovir as
an add-on therapy. The results demonstrated beneficiary prog-
nosis for this subset of patients (74). By the same token, a subset
(15–40%) of HCMV-positive CRC patients may gain benefits from
anti-viral treatment. A prospective randomized controlled trial is
critical to confirm the hypothesis.
CONCLUSION
Increasing clinical and experimental findings suggest that HCMV
may be an oncomodulatory virus for human CRC. However,

























































Chen and Chan Human cytomegalovirus in colorectal cancer
the definite role of HCMV needs to be further investigated in
a systematic manner to obtain a comprehensive and holistic
understanding. From bench to bed, the clinical relevance of the
oncomodulating effects should be testified through a multifac-
eted approach. Moreover, a randomized controlled trial is needed
to clarify whether anti-viral therapy is beneficial to CRC patients
with HCMV detected in the tumor. The results of such studies may
provide a new insight into the pathogenesis of at least a subset of
CRC and hopefully bring about new strategies for cancer therapy.
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